{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:14:04Z","timestamp":1776942844147,"version":"3.51.4"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087585","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T22:05:54Z","timestamp":1391551554000},"page":"e87585","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":94,"title":["Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study"],"prefix":"10.1371","volume":"9","author":[{"given":"Cheryl A.","family":"London","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Feo","family":"Bernabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Kisseberth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Borgatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Henson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiersten","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime F.","family":"Modiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misty D.","family":"Bear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Richard","family":"Saint-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilara","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"key":"ref1","first-page":"137","article-title":"The CRM1 nuclear export protein in normal development and disease","volume":"3","author":"KT Nguyen","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"JG Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","article-title":"CRM1-mediated nuclear export of proteins and drug resistance in cancer","volume":"15","author":"JG Turner","year":"2008","journal-title":"Curr Med Chem"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.E12-01-0045","article-title":"NESdb: a database of NES-containing CRM1 cargoes","volume":"23","author":"D Xu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/emboj.2011.287","article-title":"Ran-dependent nuclear export mediators: a structural perspective","volume":"30","author":"T Guttler","year":"2011","journal-title":"EMBO J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1128\/MCB.25.2.728-739.2005","article-title":"Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo","volume":"25","author":"D Daelemans","year":"2005","journal-title":"Mol Cell Biol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","article-title":"CRM1 is an export receptor for leucine-rich nuclear export signals","volume":"90","author":"M Fornerod","year":"1997","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, et al. (2013) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia Epub ahead of print.","DOI":"10.1038\/leu.2013.115"},{"key":"ref9","first-page":"1591","article-title":"BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood","volume":"107","author":"A Aloisi","year":"2006"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"ES Newlands","year":"1996","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-08-0858","article-title":"Identification of nuclear export inhibitors with potent anticancer activity in vivo","volume":"69","author":"SC Mutka","year":"2009","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","article-title":"Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice","volume":"144","author":"AS Azmi","year":"2012","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e14091","DOI":"10.1200\/jco.2011.29.15_suppl.e14091","article-title":"Cytotoxicity of novel, small molecule, CRM1-selective inhibitors of nuclear export (SINE) in colorectal cancer (CRC) cells","volume":"29","author":"GG Draetta","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.12231","article-title":"KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia","volume":"161","author":"J Etchin","year":"2013","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","article-title":"Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia","volume":"120","author":"R Lapalombella","year":"2012","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"McCauley D, Landesman Y, Senapedis W, Kashyap T, Saint-Martin J-R, et al. (2012) Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC). J Clin Oncol 30 Suppl: Abstract 1055.","DOI":"10.1200\/jco.2012.30.15_suppl.1055"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","article-title":"Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia","volume":"120","author":"P Ranganathan","year":"2012","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, et al. (2013) Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 41: 67\u201378 e64.","DOI":"10.1016\/j.exphem.2012.09.002"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"J Etchin","year":"2013","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.juro.2012.10.018","article-title":"CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth","volume":"189","author":"H Inoue","year":"2013","journal-title":"J Urol"},{"key":"ref21","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"CA London","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref22","first-page":"5729","article-title":"Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors","volume":"9","author":"NK Pryer","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-08-3113","article-title":"Assessment of GS-9219 in a pet dog model of non-Hodgkin\u2019s lymphoma","volume":"15","author":"DM Vail","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"LA Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e27018","DOI":"10.1371\/journal.pone.0027018","article-title":"Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer","volume":"6","author":"CA London","year":"2011","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3109\/10428194.2011.654337","article-title":"CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies","volume":"53","author":"D Ito","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1354\/vp.42-4-468","article-title":"CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma","volume":"42","author":"CM Jubala","year":"2005","journal-title":"Vet Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"BC Rutgen","year":"2010","journal-title":"Leuk Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e40078","DOI":"10.1371\/journal.pone.0040078","article-title":"Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model","volume":"7","author":"BC Rutgen","year":"2012","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V74.2.798.798","article-title":"A possible autocrine role for interleukin-6 in two lymphoma cell lines","volume":"74","author":"C Yee","year":"1989","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jcp.1041480314","article-title":"Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3","volume":"148","author":"CS Yee","year":"1991","journal-title":"J Cell Physiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2004-10-3819","article-title":"c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells","volume":"106","author":"M Gururajan","year":"2005","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/ajrcmb\/3.5.413","article-title":"Establishment of two dog mastocytoma cell lines in continuous culture","volume":"3","author":"R DeVinney","year":"1990","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2460\/ajvr.71.7.799","article-title":"Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro","volume":"71","author":"MB McMahon","year":"2010","journal-title":"Am J Vet Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00335-004-2441-x","article-title":"Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas","volume":"16","author":"S Shelly","year":"2005","journal-title":"Mamm Genome"},{"key":"ref36","unstructured":"(2011) Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol Epub ahead of print."},{"key":"ref37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2013a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"DM Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1476-5829.2010.00244.x","article-title":"Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer","volume":"9","author":"S Lynch","year":"2011","journal-title":"Vet Comp Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2307\/2533558","article-title":"Small sample inference for fixed effects from restricted maximum likelihood","volume":"53","author":"MG Kenward","year":"1997","journal-title":"Biometrics"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1091\/mbc.E12-01-0046","article-title":"Sequence and structural analyses of nuclear export signals in the NESdb database","volume":"23","author":"D Xu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/36894","article-title":"CRM1 is responsible for intracellular transport mediated by the nuclear export signal","volume":"390","author":"M Fukuda","year":"1997","journal-title":"Nature"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"CP Martins","year":"2006","journal-title":"Cell"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in vivo","volume":"445","author":"A Ventura","year":"2007","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","article-title":"CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity","volume":"118","author":"K Sakakibara","year":"2011","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","article-title":"Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas","volume":"98","author":"AS Azmi","year":"2013","journal-title":"Haematologica"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-12-1171","article-title":"CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma","volume":"12","author":"RA Salas Fragomeni","year":"2013","journal-title":"Mol Cancer Ther"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T02:08:06Z","timestamp":1597457286000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087585"}},"subtitle":[],"editor":[{"given":"Kristy L.","family":"Richards","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087585","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]}}}